A Model-based Meta-analysis on the Quantitative Relationship of Pharmacokinetics -Fasting Plasma Glucose corrected Urinary Glucose Excretion- HbA1c for Sodium Glucose co-Transporter-2 Inhibitors in T2DM Patients (Abstract) (Poster)
Jiawei Zhou, Yupeng Ren, Dongyang Liu, Bei Hu
M-002
A Simultaneous PK-diarrhea model to assess the impact of diarrhea on bioavailability of abemaciclib (Abstract) (Poster)
Accelerating Drug Development for Duchenne Muscular Dystrophy: Data Sharing and Development of Quantitative Drug Development Tools Through the Duchenne Regulatory Science Consortium (D-RSC) (Abstract) (Poster)
Klaus Romero, Alexander Berg, Jane Larkindale and members of the Duchenne Regulatory Science Consortium
M-004
An exposure response model to describe the relationship between ixekizumab concentrations and the temporal profiles of ACR response in psoriatic arthritis patients (Abstract) (Poster)
C. Steven Ernest II, Nieves Velez de Mendizabal, and Leijun Hu
M-005
An integrated biomarker and biophysical modeling approach in support of PEGylated human recombinant PH20 hyaluronidase (PEGPH20) combinatorial dosing strategy. (Abstract) (Poster)
Anas M. Fathallah, Charvi Nanavati, Darin Taverna, Jesse D. Bahn and Curtis B. Thompson
M-006
Apalutamide Population PK Model Development (Abstract) (Poster)
Andrew Castleman, Caly Chien, Daniele Ouellet, Joel S Owen
M-007
Application of platform PBPK model for auristatin-based ADCs (Abstract) (Poster)
Antari Khot, Dhaval K. Shah
M-008
Development of a Mechanistic Cell Cycle Model to Predict the in vivo Monotherapy and Combination Response of a CDK4/6 Inhibitor from in vitro Data (Abstract) (Poster)
Britton Boras, Nathan Lee, Joseph lee, Gabriel Troche, Zhenxiong Wang, Manfred Kraus, Mary E. Spilker
M-009
Evaluation of Potential Low-Dose Regimens of Oral Fixed-Dose Combination of Cytidine Deaminase Inhibitor E7727 with Decitabine (ASTX727-LD) to Minimize Decitabine-Mediated Neutropenia in Low-Risk MDS Subjects Using Systems Pharmacology Modeling (Abstract) (Poster)
A. Nikitich1, O. Demin Jr1 , O. Demin1, A. Oganesian2
M-010
Identifying Efficacious Thresholds for Bleeding Risk Reduction in Relation to Factor IX (FIX) Levels in Hemophilia B Patients Receiving IDELVION (Abstract) (Poster)
C Fosser1, J Roberts2, M Tortorici2, I Jacobs2, J Sidhu2
M-011
Manage your data comfortably: Data programming and analysis using R Shiny (Abstract) (Poster)
Anne Kmmel, Mikael Sunnaker, Henning Schmidt
M-012
Modeling and Simulation of Time to Pain Relief of a Fast-Absorbing Acetaminophen Formulation (Abstract) (Poster)
Andreas Lindauer (1), Per Olsson Gisleskog (1), Cathy Gelotte (2), Narayan Cheruvu (2) and Brenda Zimmerman (2)
M-013
Modeling methods for analyzing tumor dynamic data from basket trials (Abstract) (Poster)
Alanna S. Ocampo-Pelland, Jonathan L. French
M-014
Modelling approaches in dose finding clinical trial: Simulation-based study comparing predictive performances of model averaging and model selection. (Abstract) (Poster)
Nonlinear Pharmacokinetics of Letermovir (LET) Following Oral and IV Administration in Healthy Volunteers (Abstract) (Poster)
M. Prohn, D. Zhang, C. Davis, P. Sabato, S. Macha, A. Viberg, K. Dykstra, C. R. Cho
M-016
Population PK/PD Modeling for Evaluation of Filgotinib Efficacy in Subjects with Moderate to Severe Crohn¿s Disease (Abstract) (Poster)
Amy Meng, Shringi Sharma, Yan Xin, Florence Namour, Anita Mathias
M-017
Predicting clinical immunogenicity for biotherapeutics using a systems model of the immune response (Abstract) (Poster)
Abhinav Tiwari1, Zhiwei Zhang2, John Pappas2, Indranil Bhattacharya1, Christopher Lepsy1, Xiaoying Chen1 and Timothy P. Hickling1
M-018
R-Based VPC for Time-To-Event Models with Non-linear Hazard Functions (Abstract) (Poster)
Benjamin Rich, Samer Mouksassi
M-019
Simulo ¿ a User-Friendly Platform for Advanced Trial Simulations. A Case Study in Oncology. (Abstract) (Poster)
Belen Valenzuela, Quentin Leirens, Ruben Faelens, Per Olsson Gisleskog, Andreas Lindauer, Daniel Rshammar.
M-020
Towards Supporting Biosimilarity Assessment Without the Need for Efficacy Trial: Neupogen (Abstract) (Poster)
Aberra Fura, Jogarao Gobburu
M-021
Evaluation of subcutaneous bioavailability of CNTO 3157 in healthy volunteers using a two-compartment population PK model with additional non-linear clearance function (Abstract) (Poster)
Chao Han, Christina L. Mayer, Qun Trina, Hugh M. Davis, Donald L. Heald
M-022
Modeling of moxifloxacin pharmacokinetics and fecal microbiota disruption in healthy volunteers (Abstract) (Poster)
Charles Burdet (1,2), Thu Thuy Nguyen (1), Jean de Gunzburg (3), Stphanie Ferreira (4), Annie Ducher (3), Xavier Duval (1,2), Marina Varastet (3), Antoine Andremont (1,2), France Mentr (1,2)
M-023
Population Pharmacokinetics of Sarilumab in Patients With Rheumatoid Arthritis (Abstract) (Poster)
Christine Xu1, Yaming Su2, Anne Paccaly3, Vanaja Kanamaluru1
M-024
Mechanistic projection of bortezomib target-mediated disposition, blood target inhibition and drug-drug interactions using an integrated PBPK/PD approach (Abstract) (Poster)
Shinji Iwasaki1, Andy Zhu1, Michael Hanley2, Karthik Venkatakrishnan2, Cindy Xia1
M-025
The influence of age on the disposition of cyclophosphamide and its metabolites in infants and young children with brain tumors: A population pharmacokinetic analysis (Abstract) (Poster)
Anil R. Maharaj, John C. Panetta, Amar Gajjar, Clinton F. Stewart
M-026
A Population Pharmacokinetic/Toxicity Model for the Reduction of Platelets during a 48-hr Continuous Intravenous Infusion of the Histone Deacetylase Inhibitor Belinostat (Abstract) (Poster)
Cody J. Peer1, Andrew K.L. Goey1, Tristan M. Sissung1, Sheryl Erlich1, Richard Piekarz2, Sanjeeve Balasubramaniam3, Susan E. Bates4, William D. Figg1,5
M-027
Two-Pore Minimal PBPK Model to Describe the Disposition of IgG Antibody in Human Subjects (Abstract) (Poster)
D. Hardiansyah, CM. Ng
M-028
Integrated Three-Analyte Population Pharmacokinetic (PPK) Model for Antibody-Drug-Conjugates (ADC) in Patients with Non-Hodgkin Lymphoma (Abstract) (Poster)
Dan Lu1, Leonid Gibiansky2, Sandhya Girish1, Priya Agarwal1, Chunze Li1, Dale Miles1, Randall Dere1, Jamie Hirata1, Yu-Waye Chu1, Jin Yan Jin1
M-029
A general empirical model for renal drug handling in population pharmacokinetic analyses (Abstract) (Poster)
Daniel F.B. Wright, Stephen B. Duffull
M-030
A dynamic mathematical model of bile acid clearance in HepaRG cells (Abstract) (Poster)
Daniel Kaschek, Ahmad Sharanek, Andr Guillouzo, Jens Timmer, Richard J. Weaver
M-031
Clinical responses to ERK inhibition in BRAFV600E-mutant Colorectal Cancer Predicted Using a QSP-based Computational Model (Abstract) (Poster)
Daniel C. Kirouac, Gabriele Schaeffer, Jocelyn Chan, Mark Merchant, Christine Orr, Lichuan Liu, Alex Huang, John Moffat, Kapil Gadkar, Saroja Ramanujan
Daniela J Conrado1, Jackson Burton1, Timothy Nicholas2, Brian Corrigan2, Kuenhi Tsai3, Danny Chen2, Vikram Sinha3, Sreeraj Macha3, Julie Stone3, Brian Willis4, Ian Watson4, Massimo Bani5, Pierandrea Muglia5, Wenping Wang6, Volker D Kern1, Stephen Arneri¿1, Diane Stephenson1, Klaus Romero1 on behalf of the Coalition Against Major Diseases (CAMD) and Critical Path for Parkinson¿s (CPP)
M-033
Web-based app for mycophenolate mofetil dosing recommendation in pediatric and adult transplant patients (Abstract) (Poster)
R2SAS, R2SAS2PDF & SAS2SHINY: Seamless R and SAS (Abstract) (Poster)
Daren Austin, Isabelle Pouliquen and Pragathi Kotha Venkata
M-035
Population Pharmacokinetic (POPPK) Model for Ertugliflozin in Healthy Subjects and Type 2 Diabetes Mellitus (T2DM) Patients (Abstract) (Poster)
Daryl J Fediuk1, Kevin Sweeney1, Susan Zhou2, Vikas Kumar1, Vaishali Sahasrabudhe1
M-036
Costing ¿the¿ MTD: What Is the Economic and Human Cost of 1-Size-Fits-All Dose Finding in Oncology? (Abstract) (Poster)
David C. Norris
M-037
Multi-state modeling and simulation of patient trajectories after allogeneic hematopoietic stem cell transplantation (allo-HSCT) to inform drug development (Abstract) (Poster)
David James, Jennifer Ng, Jiawei Wei, and Marc Vandemeulebroecke
M-038
Clinical Trial Simulations to Guide Dose Escalation in First Time In Human (FTIH) for a Drug With Absolute Individual Exposure Limits (Abstract) (Poster)
David Tenero, Navin Goyal
M-039
NCA-ADAPT: comprehensive software for pharmacokinetic non-compartmental analysis (Abstract) (Poster)
Yaping Zhang and David Z. D¿Argenio
M-040
Lead Antimalarial Identification Using In Silico Prediction Methods and Simulation (Abstract) (Poster)
Denise Morris, Walt Woltosz, Michael Lawless, Ted Grasela, Robert Clark
M-041
Application of PK-PD Modeling in Understanding Bystander Effect for Antibody Drug Conjugates (Abstract) (Poster)
Aman P. Singh and Dhaval K. Shah
M-042
Population Pharmacokinetic-Pharmacodynamic Modeling of a Novel TAFIa Inhibitor DS-1040 in Healthy Subjects (Abstract) (Poster)
Dongwoo Kang, Jin Zhou, Michael Grosso, Ophelia Yin
M-043
Ocular Pharmacokinetics and Pharmacodynamics of Ketorolac Tromethamine in Neonatal Sprague Dawley Rats (Abstract) (Poster)
Sree Kurup, Jun Qu, Jacob Aranda, Kay Beharry and Donald E. Mager
M-044
Development of a PBPK model for anti-transferrin (TfR) antibodies to predict brain and systemic pharmacokinetics (Abstract) (Poster)
Veena Thomas, Patrick Glassman, Joseph Balthasar
M-045
A population model for respiratory syncytial virus (RSV) kinetics using transit compartments based on human challenge data (Abstract) (Poster)
Dymphy Huntjens1, Julia Korell2 and Bruce Green2
M-046
A quantitative framework for immune liver diseases: understanding HBV infection (Abstract) (Poster)
Eduardo Asn-Prieto1, Zinnia P Parra-Guillen1, Jose David Gomez Mantilla1, Joris Vandenbossche2, Kym Stuykens2, Xavier Woot de Trixhe2, Juan Jos Perez-Ruixo2, Iaki F. Troconiz1
M-047
A mechanistic population pharmacokinetic model of abemaciclib and its metabolites and the impact of diarrhea (Abstract) (Poster)
Emmanuel Chigutsa, Siva Rama Prasad Kambhampati, Amanda Karen Sykes, Maria M. Posada, P. Kellie Turner
M-048
Population pharmacokinetics and pharmacodynamics of the CFTR potentiator ivacaftor in patients with cystic fibrosis and a G551D-CFTR mutation (Abstract) (Poster)
Eric Haseltine, John Mondick, Varun Garg, and Julie Lekstrom-Himes
M-049
Use of Python and Spotfire for Quality Control of Pharmacometric Analysis Dataset Preparation (Abstract) (Poster)
Erin Dombrowsky, Yiwen Luo, Neelima Thanneer
M-050
Modelling aspects of sequential knowledge integration using Bayesian PK/PD (Abstract) (Poster)
Fabiola La Gamba (1,2), Tom Jacobs (1), Helena Geys (1,2), Christel Faes (2)
M-051
Using Hamiltonian Monte-Carlo to design longitudinal count studies accounting for parameter and model uncertainties (Abstract) (Poster)
Florence Loingeville, Thu Thuy Nguyen, Marie-Karelle Riviere, France Mentr
M-052
Model-based meta-analysis of topical treatments for atopic dermatitis: Eczema Area and Severity Index (EASI) as an efficacy endpoint (Abstract) (Poster)
Frank Jen*, William C Ports, Jocelyn Papacharalambous, Cunshan Wang, Sima Ahadieh, and Vivek S Purohit
M-053
Model-based analysis of clinical assays for assessing the efficacy of vaccines against Respiratory Syncytial Virus (RSV) (Abstract) (Poster)
Galina Lebedeva, Nikolai Pakhomov, Oleg Demin Jr, Oleg Demin
M-054
Model Based Development Strategies for Covalent Molecules (Abstract) (Poster)
Gary Mo, John Strelow, Bradley Ackerman and Michael Heathman
M-055
Physiologically-based pharmacokinetic (PBPK) model to describe the disposition of pyronaridine (Abstract) (Poster)
John K. Diep (1,2), Mary A. Lingerfelt (3), Sean Ekins (3), Gauri G. Rao (1,2)
M-056
A Whole-Body Physiologically Based Pharmacokinetic Model of Afatinib in Mice and Scale-Up to Humans (Abstract) (Poster)
Ronilda D'Cunha
M-057
PHARMACOKINETIC AND PHARMACODYNAMIC MODEL OF SYNTHETIC HUMAN HEPCIDIN LJPC-401 FOLLOWING SINGLE DOSE ADMINISTRATION IN DOGS (Abstract) (Poster)
H. Jin1, W. Krzyzanski2, S. Patel1, R. Marsden1, J. Rolke1, A. Seacat1
M-058
Evaluation of the Impact of Time-Dependent Pharmacokinetics on Individual Exposure Estimation (Abstract) (Poster)
Haitao Yang, Xiaoning Wang, Xu Steven Xu, Liping Zhang, Yan Feng
M-059
Steps Towards a Robust Generic Method for Deconvolution Directly on Pharmacokinetic Profiles (Abstract) (Poster)
Kristian Moss Bendtsen & Hanne H.F. Refsgaard
M-060
PKexplore - An Interactive Web Application Using R Shiny Package for Pharmacometric Exploratory Analysis and Modeling (Abstract) (Poster)
Mechanistic PK/PD Modeling and Simulation of The Follistatin¿Myostatin/Activin A¿ActRIIB Pathway (Abstract) (Poster)
Haojing Rong, Paul Jasper, Zhiwei Zhang, Andrea Iskenderian, David Ehmann, Qingwei Deng, Kathleen Palmieri, Bob Crooker, Dianna Lundberg, Chuan Shen, Angela Norton, Kening Song, John McNulty, Haobin Lou, John Tolsma, Devin Welty
M-062
POPULATION PHARMACOKINETICS OF OXYTETRACYCLINE IN GIANT DANIO AFTER EXTENDED BATH IMMERSION: EFFECT OF CALCIUM AND PREDICTION OF DOSE FOR BATH THERAPY (Abstract) (Poster)
HARDIK CHANDASANA1*, BRYAN VORBACH2, ROY P. YANONG2, HARTMUT DERENDORF1
M-063
Population pharmacokinetic/pharmacodynamic (PK/PD) Model for BIIB059, a Monoclonal Antibody (mAb) for the Treatment of Systemic and Cutaneous Lupus Erythematosus (Abstract) (Poster)
(1,*) Sonja Hartmann, (1,*) Konstantinos Biliouris, (2) Lauren Stevenson, (2) Chase Shen, (2) Ivan Nestorov, (2) Himanshu Naik, (1) Lawrence J. Lesko, (1) Mirjam N. Trame
M-064
A Pharmacodynamic driven model which incorporated the correlation of pulmonary and cardiac effects of fenoterol in asthmatic patients after different routes of administration (Abstract) (Poster)
Drescher Stefanie, Bulitta Jrgen, Hochhaus Gnther
M-065
Longitudinal tumor dynamic modeling in non-small cell lung cancer (NSCLC) patients treated with gefitinib (Abstract) (Poster)
A PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODEL ADEQUATELY PREDICTED THE HUMAN PHARMACOKINETIC PROFILES OF YH4808, A NOVEL POTASSIUM-COMPETITIVE ACID BLOCKER, TO TREAT GASTRIC ACID RELATED DISEASE (Abstract) (Poster)
HYUN A LEE
M-067
A Quantitative Systems Pharmacology Approach For Predicting Pharmacological Interactions Between Antipsychotic Drugs. Validation Using Electronic Health Records (Abstract) (Poster)
Hugo Geerts, Athan Spiros, Giouliana Kadra, Richard Hayes, Robert Stewart
M-068
Ex-vivo exposure-response characterization of antitumor activity of anti CD123 X CD3 DuoBody in primary acute myeloid leukemia (AML) bone marrow samples (Abstract) (Poster)
Indrajeet Singh, Nikita Parab, Khaja Syed, Xiling Jiang, Yu-Nien Sun, Fei Huang, Kate Sasser, Anna Kalota
M-069
Automated framework for global sensitivity analysis for the GastroPlus¿ physiologically-based pharmacokinetic model (Abstract) (Poster)
Megerle L. Scherholz, Zilong Wang, James Forder, Marianthi Ierapetritou, Ioannis Androulakis
M-070
A SimBiology-based GUI tool for PKPD modeling in drug development (Abstract) (Poster)
Joint modeling of overall survival and circulating biomarker dynamics in melanoma patients treated with IFN-2b (Abstract) (Poster)
Itziar Irurzun-Arana (1), Eduardo Asn-Prieto (1), Salvador Martn-Algarra (2) and Iaki F. Trocniz (1)
M-072
Modeling viral kinetics predicts a rapid establishment of the cytotoxic immune response targeting distinct infected cell compartments in SIV controller macaques (Abstract) (Poster)
V. Madelain1, C. Passaes2, A. Millet3, V. Avettand-Fenoel3, C. Rouzioux3, N. Bosquet4, R. Legrand4, B. Vaslin4, A. Saez-Cirion2, J. Guedj1
M-073
Data Sharing and Standardization to Expand a Patient-Level Database of a Regulatory Endorsed Clinical Trial Simulator for Alzheimer Disease (Abstract) (Poster)
Jackson Burton 1, Daniela J Conrado 1, Brian Corrigan 2, Timothy Nicholas 2, Danny Chen 2, Julie Stone 3, Vikram Sinha 3, Brian Willis 4, Wenping Wang 5, Volker D. Kern 1, Stephen P Arneri¿ 1, Klaus Romero 1
M-074
Exact Gradients Improve Parameter Estimation in Nonlinear Mixed Effects Models with Stochastic Dynamics (Abstract) (Poster)
Helga Kristn lafsdttir(1), Jacob Leander(1,2,3), Joachim Almquist(1,4) , Mats Jirstrand(1)
M-075
Modeling Predicts Kidney Function for Patients after a Kidney Transplant (Abstract) (Poster)
Jagdeep T. Podichetty, Marie B. Nielsen, Henrik Birn, Johnny T. Ottesen
M-076
A systems pharmacology modeling approach for assessing the clinical haematoxicity of anti-cancer agent combinations (Abstract) (Poster)
James Lu, Sarit Rabbie, Tarjinder Sahota, Lenka Oplustil O¿Connor, Claire Crafter, Sabina Cosulich, Alexander MacDonald
M-077
Systemic pharmacotherapy support during chronic kidney disease using a novel conceptual framework (Abstract) (Poster)
Eduard Schmulenson, Jan-Frederik Schlender, Sebastian Frechen, Stephan Schmidt, Ulrich Jaehde
M-078
Population Pharmacokinetics and Pharmacodynamics Analysis of Selumetinib and its Metabolite in Phase 1 Subjects and Patients with Non-small Cell Lung Cancer (Abstract) (Poster)
Xiao Tong, Hongmei Xu, David Carlile, Helen Tomkinson, Nidal Al-Huniti, Diansong Zhou
M-079
Prediction of progression free survival using tumor dynamics in non-small cell lung cancer (NSCLC) patients treated with selumetinib: A joint modeling approac (Abstract) (Poster)
Xiao Tong, James Dunyak, Diansong Zhou, Dmitry Onishchenko, David J, Carlile, Helen Tomkinson, Gabriel Helmlinger, Nidal Al-Huniti, Hongmei Xu
M-080
Performance of joint modeling packages in R for predicting progression free survival with longitudinal tumor measurements (Abstract) (Poster)
Xiao Tong, Hongmei Xu, Diansong Zhou, James Dunyak, Nidal Al-Huniti
M-081
Harnessing meta-analysis to develop an oncology patient population for physiologically based pharmacokinetic (PBPK) modelling with application to AstraZeneca oncology projects (Abstract) (Poster)
Venkatesh Pilla Reddy1*, Emily Schwenger2, Ganesh Moorthy2, Pradeep Sharma3, Helen Tomkinson2, Eric Masson2 and Karthick Vishwanathan2
M-082
glioblastoma multiforme (GBM) or brain metastatic (BM) patients (Abstract) (Poster)
Pharmacokinetic-pharmacodynamic modeling approach to inform the level and duration of HER2 kinase inhibition required to demonstrate the efficacy in subcutaneous xenograft and orthotopic mouse tumor models (Abstract) (Poster)
Venkatesh Pilla Reddy1, Jinqiang Zhang2, Mei Wang2, Klas Petersson3, Teresa Klinowska4 and Owen R. Jones1
M-084
Drug-Disease modeling: a practical workflow from model development to simulations (Abstract) (Poster)
Victor Sokolov1, Lulu Chu2, Yuri Kosinski1, Nidal Al-Huniti2, Robert Fox2, Henning Schmidt3, Dmitry Onishchenko1, Veronika Voronova1, Kirill Zhudenkov1, Gabriel Helmlinger2, Kirill Peskov1
M-085
Differentiation of anti-PCSK9 antibodies and synthesis inhibitors using Drug-Disease modeling of lipoprotein metabolism (Abstract) (Poster)
Victor Sokolov1, Anton Goncharov1, Eva Hurt-Camejo2, Catarina Nilsson3, Kirill Zhudenkov1, Stanko Skrtic3, Bengt Hamrn3, Kirill Peskov1, Gabriel Helmlinger1, Rasmus Jansson-Lfmark2
M-086
Drug-disease modeling of renal glucose reabsorption in healthy and diabetes subjects: Investigating differences in SGLT2 inhibitors efficacy (Abstract) (Poster)
Tatiana Yakovleva1, Victor Sokolov1, Lulu Chu2, Robert C. Penland2, Weifeng Tang2, Peter J. Greasley2, Kirill Peskov1, Gabriel Helmlinger2, David W. Boulton2
M-087
Tau propagation systems pharmacology model based on three-component memory-retrieval system predicts heterogeneous response to immunotherapy in brain regions (Abstract) (Poster)
Tatiana Karelina (1), Alexander Stepanov (1), Timothy Nicholas (2)
M-088
Mechanistic model for the role of the microglial cells in amyloid accumulation and its modulation by immunotherapy (Abstract) (Poster)
Tatiana Karelina (1), Alexander Stepanov (1), Theresa Yuraszeck (2), Dean Hickman (2), Steve Wood (2)
M-089
Exposure-Response Analyses to Support Dosing Recommendations for RBP-6000 Buprenorphine Monthly Formulation in Subjects with Opioid Use Disorder (Abstract) (Poster)
Long-term Exposure of RBP-6000 Buprenorphine Monthly Formulation for the Treatment of Opioid Use Disorder: A Combined Population Pharmacokinetic Analysis (Abstract) (Poster)
Aksana K. Jones, Eliford Ngaimisi, Mathangi Gopalakrishnan, Malcolm Young, Celine M. Laffont
M-091
PhysioPD(TM) Research Utilizes Mechanistic Physiological Models to Enhance Immunology Research and Drug Development (Abstract) (Poster)
Katherine Kudrycki, Michael Weis, Meghan Pryor, Rebecca Baillie, Vincent Hurez, Douglas Chung, Mike Reed, Christina Friedrich
M-092
Mechanistic Modeling Using a PhysioPD Research Platform Facilitates Identification of Key Pathways Involved in Skin Aging and Potential New Anti-aging Technologies. (Abstract) (Poster)
Katherine Kudrycki1, Michael Weis1, Christina Friedrich1, Robert Binder2, Robert Isfort2, Ryan Tasseff2, Charlie C. Bascom2
M-093
Integrated Modeling of the Receptor/Gene/Protein-mediated Pharmacodynamic Actions of Corticosteroids on Tyrosine Aminotransferase Activity, Hepatic Glucose Regulation, and Immunosuppression in Rat Liver (Abstract) (Poster)
Vivaswath S. Ayyar, Siddharth Sukumaran, Richard R. Almon, Debra C. DuBois, Jun Qu, William J. Jusko
M-094
Circadian modeling of core clock gene expression in four tissues of rats (Abstract) (Poster)
Panteleimon D. Mavroudis, Richard R. Almon, Debra C. DuBois, William J. Jusko
M-095
Quantitative Pharmacological Assessment of Trastuzumab-Anthracycline Induced Cardiotoxicity (Abstract) (Poster)
Tanaya Vaidya, Sihem Ait-Oudhia
M-096
Bench-to-Bedside Translation of Everolimus Efficacy in Hepatocellular Carcinoma Using a Multiscale Quantitative Systems Pharmacological Approach. (Abstract) (Poster)
Anusha Ande, Sihem Ait-Oudhia
M-097
Systems Pharmacology Modeling in R, powered by Shiny (Abstract) (Poster)
Henning Schmidt, Anne Kmmel, Mikael Sunnaker
M-098
Population Pharmacokinetic and ExposureResponse Models of Once-Weekly Exenatide (Abstract) (Poster)
Robert C. Penland, Sergey Aksenov, Mats Ngrd, Susanne Johansson, David W. Boulton, Brenda Cirincione
M-099
Simulated Exenatide Plasma Concentrations in Human Subjects Following Late, Shifted, or Missed Dosing of Exenatide Once-Weekly Suspension (Abstract) (Poster)
Robert C. Penland, Mats Ngrd, Susanne Johansson, David W. Boulton
M-100
AZRsim ¿ An integrated platform for PK/PD and QSP model simulation in drug development (Abstract) (Poster)
Robert Fox1, Lulu Chu1, Christopher Penland1, Henning Schmidt2, Devin Pastoor1, Imad Ali3, Gabriel Helmlinger1, Craig Lambert1, Nidal Al-Huniti1
Robert Fox1, Henning Schmidt2, Devin Pastoor1, Imad Ali3, Craig Lambert1, Helena Edlund1, Nidal Al-Huniti1
M-102
A NONMEM Data Strategy ¿ Mitigating differing workflows, perspectives and processes (Abstract) (Poster)
Robert Fox1, Nidal Al-Huniti1
Stats Spotlight Session
(Abstract) (Poster)
T-001
Application of Item Response Theory Model for Mayo Score in Ulcerative Colitis in Early Signs of Efficacy Trials (Abstract) (Poster)
Camille Vong, Elena Soto, Simon Kirby, Scott Marshall, Steven W Martin
T-002
Meta-analysis of HbA1c and hypoglycemic event rates of meal-time insulins in randomized clinical trials in T1DM subjects: exploration of POC trial design options (Abstract) (Poster)
Bhargava Kandala1, Mark Lovern2, Jos Lommerse2, Craig Fancourt1, Pavan Vaddady1, Jaap Mandema2, Thomas Kerbusch2, Sandra A.G. Visser1
T-003
Systemization of Time-to-Event Analyses for Pharmacometric Applications (Abstract) (Poster)
Analysis of covariance with pre-treatment/demographic measurements in parallel clinical pharmacology comparability studies for biologics (Abstract) (Poster)
Clinical trial simulations based on a meta-analysis of studies in patients with locally advanced and/or metastatic adenocarcinoma pancreatic cancer receiving gemcitabine (GEM) alone or in combination. (Abstract) (Poster)
Dana Nickens, Meg Bennetts, Holger Thurm, Carla Hernandez, Sima Ahadieh, Michael Amantea
T-006
Simulation re-estimation and Baysian Optimal Design for Population Pharmacokinitic Studies (Abstract) (Poster)
Kairui Feng1, Robert H. Leary1, Michael Dunlavey1, Amin Rostami-Hodjegan1,2
T-007
Exposure-Response Analysis of Asthma Exacerbation Rate Confirmed Optimal 30 mg Q8W Benralizumab Dose for Treatment of Severe Asthma (Abstract) (Poster)
Yen Lin Chia1, Bing Wang1, Binbing Yu2, Peter Barker3, Mitch Goldman3, Lorin Roskos2
T-008
The effect of rivaroxaban exposure and clinical risk factors on efficacy and safety outcomes in patients with acute coronary syndromes (Abstract) (Poster)
Xiaoyu Yan1, Gary Peters1, Dirk Garmann2, Stefan Willmann2, Anne Hermanowski-Vosatka1, Partha Nandy1, Alexander Solms2, Scott D. Berkowitz2, Theodore Spiro2, Keith AA. Fox3, Jeffrey I. Weitz4, Stephan Schmidt5, Liping Zhang1
T-009
Is Complete Remission Rate Predictive of Median Overall Survival? A Model-Based Meta-Analysis in Patients with Acute Myeloid Leukemia (Abstract) (Poster)
Matthew L. Zierhut, Thomas Puchalski, Aleksandra Rizo, Liang Xiu, Hong Tian, Amarnath Sharma, Yusri Elsayed, Partha Nandy
T-010
Comparison of diagnostics using model-based post-processing for fast automated model building (Abstract) (Poster)
Moustafa M.A. Ibrahim, Rikard Nordgren, Maria C. Kjellsson, Mats O. Karlsson
T-011
Interactive Exposure-Response Analysis Using R Shiny (Abstract) (Poster)
nlmixr: an open-source package for pharmacometric modeling in R (Abstract) (Poster)
Rik Schoemaker1,*, Matt Fidler2, Yuan Xiong3, Justin Wilkins1, Mirjame Trame2, Christian Laveille4, Wenping Wang2
T-013
Gaining Efficiency by Combining Analytical and Numerical Solutions to Solve ODE Systems: Implementation in Stan and Application in Bayesian PKPD Modeling (Abstract) (Poster)
Charles C. Margossian, William R. Gillespie
T-014
Exploration of factors impacting covariate identification in concurrent population pharmacokinetic (PopPK) modelling for parent and metabolite concentrations (Abstract) (Poster)
Jingtao Lu, Diansong Zhou, Hongmei Xu, Helena Edlund, Nidal Al-Huniti, James Li
T-015
On multiple imputation using chained equations (MICE) and missing covariates in population pharmacokinetic analysis (Abstract) (Poster)
Ayyappa Chaturvedula1,*, Ene I. Ette2
T-016
Performance of a dummy category (DC) in handling missing covariates in pharmacometric analysis (Abstract) (Poster)
Ayyappa Chaturvedula1,*, Ene I. Ette2
T-017
Age Is a Statistically Significant Predictor of the Within Subject Variability in Dabigatran Pharmacokinetics (Abstract) (Poster)
Mario Gonzlez-Sales, Jianghong Fan, Lanyan Fang, Meng Hu, Bing Li, Robert Lionberger and Liang Zhao.
T-018
Dynamic prediction of treatment response and probability of exacerbation in COPD using joint modeling (Abstract) (Poster)
Kirill Zhudenkov 1, Dina Chernikova 1, Dmitry Onishchenko 1, Nidal Al-Huniti 2a, Kirill Peskov 1, Gabriel Helmlinger 2a, Ulf Eriksson 2a, Robert Palmr 2a, Alexandra Jauhiainen 2b
T-019
Correlation between progression-free and overall survival in a meta-analysis of aggregated survival data from patients with non-small cell lung cancer (Abstract) (Poster)
Sergey Aksenov, Daniel Lee, Helena Edlund, Kaitlyn Minchella, Hongmei Xu, James Dunyak, Nidal Al-Huniti
T-020
Use of Linear Median Quantile Mixed Modelling (LMQM) for Analyzing Moxifloxician (MOX) Concentration and Change from Baseline in QTc relationship (C-¿QTc) to Demonstrate Positive Control (PC) (Abstract) (Poster)
J. Li, J. Lu, N. Al-Huniti
T-021
Improving interim and subgroup analyses of oncology trials with joint modeling of time-evolving tumor size and survival (Abstract) (Poster)
James Dunyak, Dmitry Onishchenko, Eric Masson, Gabriel Helmlinger, Kirill Peskov, Don Stanski, Nidal Al-Huniti
T-022
Dynamic Metrics-based Biomarkers to Predict Responders to Checkpoint Immunotherapy (Abstract) (Poster)
Can Liu, Hua He, Yanguang Cao
T-023
A Systems Pharmacology Approach to Support Translational Research in Immunotherapy and Its Combination with Chemotherapy (Abstract) (Poster)
Emily Mick
T-024
Physiologically-based, Mechanistic Pharmacokinetic/Pharmacodynamic Modeling to Support Development of T Cell Redirecting Bispecific Agents (Abstract) (Poster)
Xiling Jiang, Xi Chen, Donald L. Heald, Weirong Wang
T-025
A Quantitative Systems Pharmacology Model to Support Development of Combinational Therapy for Non-Small Cell Lung Cancer (NSCLC) (Abstract) (Poster)
Songmao Zheng1, Yue Guo1, Xi Chen1, Douglas Chung2, Mike Reed2, Donald Heald1 and Weirong Wang1
T-026
Pharmacokinetic/Receptor Occupancy/Pharmacodynamic Modeling of FR104, an Anti-CD28 Pegylated Fab' Ab, in Healthy Subjects with or without KLH Challenge (Abstract) (Poster)
Songmao Zheng1, Ian Gourley2, Bernard Vanhove3, Weirong Wang1
T-027
Mechanistic modeling of Natural Killer cell dynamics and cytokine production to support systems pharmacology modeling of the immune response (Abstract) (Poster)
Oleg Demin, Oleg Demin Jr
T-028
Quantitative Systems Pharmacology Modeling to Evaluate and Prioritize Targets (CD19, CD20, CD22) for Bispecific Antibodies and CAR-T in Acute Lymphoblastic Leukemia (Abstract) (Poster)
Oleg Demin Jr1, Antonina Nikitich1
T-029
Systems Pharmacology Modeling for Optimization of Target Therapy for Melanoma (Abstract) (Poster)
Dmitry Shchelokov1, Oleg Demin Jr1
T-030
Mechanistic Modeling of Co-stimulatory and Co-inhibitory Surface Molecules Effect on Cell-to-cell Interactions (Abstract) (Poster)
Oleg Demin Jr
T-031
Considerations in Selection of PK Indices Driving Efficacy of Antimicrobial Agents-Pitfalls in PK-PD Model Selection (Abstract) (Poster)
Differentiation of basal insulins in randomized clinical trials in T2DM subjects: a model-based meta-analysis of HbA1c and hypoglycemic event rates (Abstract) (Poster)
Pavan Vaddady1, Mark Lovern2, Jos Lommerse2, Craig Fancourt1, Bhargava Kandala1, Jaap Mandema2, Ferdous Gheyas1, Thomas Kerbusch2, Sandra A.G. Visser1
T-033
Pharmacodynamic (PD) Model of Neutrophil Margination to Describe Transient Effect of Single-Dose Sarilumab on Absolute Neutrophil Count (ANC) in Patients With Rheumatoid Arthritis (RA) (Abstract) (Poster)
Pavel Kovalenko1, Anne Paccaly1, Anita Boyapati1, Christine Xu2, John D. Davis1, A. Thomas DiCioccio1
T-034
Population Pharmacokinetic Analysis of Dupilumab Using Early Phase and Phase 3 Data (Abstract) (Poster)
Pavel Kovalenko1, John D. Davis1, Meng Li2, A. Thomas DiCioccio1
T-035
An Integrated Approach to Apply Quantitative Systems Pharmacology Model of Diabetes in Early Phase of Diabetes Research (Abstract) (Poster)
Jeanne S Geiser, Karen B Schneck, Jenny Y Chien
T-036
Prospective Liver Safety Comparison of Two Treatments for Autosomal-Dominant Polycystic Kidney Disease (ADPKD) Using Quantitative Systems Toxicology Modeling (Abstract) (Poster)
Translational PK/PD modeling approaches for assessment of therapeutic index of an antibody-drug conjugate HKT288 (Abstract) (Poster)
Xu Zhu, Ivana Liric, Tao Ji, Carl Uli Bialucha, Scott Collins, Jason Faris, Meghan Flaherty, Jian Xu
T-038
Using pre-dose or time-matched baseline ECG data provides the same conclusions from concentration-QT/QTc interval prolongation modeling-Results from two case studies of oncology drugs with positive (osimertinib) and neutral (olaparib) effects on cardiac repolarization (Abstract) (Poster)
Jingtao Lu, Maria Learoyd, Karthick Vishwanathan, Hongmei Xu, Martin Johnson, Helen Tomkinson, Nidal Al-Huniti, Eric Masson, Jianguo Li
T-039
Population pharmacokinetics of lenalidomide in patients with haematological cancer (Abstract) (Poster)
Jim H. Hughes(1, 2), Stephanie E. Reuter(2), Richard N. Upton(1, 2), Mitch A. Phelps(3), David J.R. Foster(1, 2)
T-040
Second order Taylor expansion of likelihood-based models (Abstract) (Poster)
Yasunori Aoki, Joakim Nyberg, Mats O. Karlsson
T-041
Assessing the Role of Quantitative Systems Pharmacology Modeling in the Early Stage Drug Development for Urea Cycle Disorders. (Abstract) (Poster)
Rebecca Baillie,, Michael Weis, Mike Reed
T-042
Application of the PhysioPDTM Research Platform, a Quantitative Systems Pharmacology (QSP) Model, to Evaluate xCT Inhibition as a Target for Central Nervous System Diseases. (Abstract) (Poster)
CM Friedrich1, CM Witt1, MM Pryor1, T Rooney2, A Genevois-Borella2, MC Obinu2, A Guerreiro2, J Konop2, MJ Reed1, Z Bocskei2
T-043
Mathematical Modeling of Patient Response and Non-response to Therapy (Abstract) (Poster)
Rebecca Baillie1, Michael Weis1, Katherine Kudrycki1, Michael Reed1, Himanshu Naik2, Deborah Demanno2, Stephanie Moran2, Majid Vakilynejad2, Ananth Kadambi1
T-044
Assessing Sodium-Glucose Co-Transporter Inhibition Using a PhysioPD-Style Model (Abstract) (Poster)
Rebecca Baillie1,*, Michael Weis1, Hans-Christoph Schneider2, Ashley Strougo2, Juliana Oliveira3, Thomas Klabunde2, Mike Reed1
T-045
Parallel computing of nonlinear mixed modeling using OpenMP: Part 1. first-order approximation method (Abstract) (Poster)
Ji-Jin Lee, Min-Gul Kim
T-046
Parallel computing of nonlinear mixed modeling using OpenMP: Part 2. first-order conditional estimation with interaction approximation method (Abstract) (Poster)
Ji-Jin Lee, Min-Gul Kim
T-047
A Novel Modified Wald¿s Approximated Method for Efficient Covariate Selection in Population Pharmacokinetics Analysis (Abstract) (Poster)
Yixuan Zou, Fei Tang, Chee M. Ng
T-048
An Automated Algorithm in Determining Optimal Monte-Carlo Sample Size to Achieve Desirable Random Noise of Monte Carlo Parametric Expectation Maximization (MCPEM) in Population Pharmacokinetic Analysis (Abstract) (Poster)
Yixuan Zou, Chee M. Ng
T-049
Using Novel Monte-Carlo Parametric Expectation Maximization Based Wald¿s Approximation Method with Backward Elimination to Develop Disease Progression Model for Metastatic Prostate Cancer Patients Treated with Leuprorelin (Abstract) (Poster)
Yixuan Zou, Fei Tang, Jeffery C. Talbert and Chee M. Ng
T-050
Hitting the Moving Target in Circadian Rhythm: The Application of Systems Pharmacology Model in the Development of a CK1 Inhibitor (Abstract) (Poster)
Cheng Chang, Francois Gaudreault, Arthur Simen, Travis Wager, Jaekyoung Kim, Kyoung-Ae Kim, Taeshin Park, John Tolsma
T-051
A PKPD analysis of circulating biomarkers and their relationship to the tumor size time-course in atezolizumab treated non-small cell lung cancer patients (Abstract) (Poster)
I Netterberg1, 2, CC Li 3, L Molinero4, NR Budha3, S Sukumaran3, M Stroh4, EN Jonsson2, LE Friberg1,2
T-052
Exploring inductive linearization and its convergence properties for systems of nonlinear ordinary differential equations (Abstract) (Poster)
Chihiro Hasegawa [1,2], Stephen B. Duffull[1]
T-053
Development of a compound criterion and model qualification for scale reduction of complex systems models (Abstract) (Poster)
Chihiro Hasegawa [1,2], Stephen B. Duffull[1]
T-054
PharmTeX: a LaTeX-based open-source platform for automated reporting workflow (Abstract) (Poster)
Christian Hove Rasmussen (1), Timothy Nicholas (2)
T-055
Using Mechanistic Physiological Models to Investigate Responder / Non-Responder Attributes Retrospectively and Prospectively to De-Risk Drug Development (Abstract) (Poster)
Christina Friedrich, Mike Reed, Rebecca Baillie, Katherine Kudrycki, Michael Weis, Meghan Pryor, Douglas Chung
T-056
PhysioPDTM Research Enhances Dermatology Research and Drug Development Using Mechanistic Physiological Modelling (Abstract) (Poster)
Christina Friedrich*, Katherine Kudrycki, Michael Weis, Meghan Pryor, Vincent Hurez, Rebecca Baillie, Mike Reed
T-057
Population Pharmacokinetics of Mycophenolic Acid and its Metabolites in Liver Transplant Recipients (Abstract) (Poster)
Characterize and Compare the Oral Pharmacokinetics of Luteolin in Mini Pigs and Beagle Dogs (Abstract) (Poster)
Tianyi Hua, Dan Li, Kai Wang, Huidi Jiang, Meihua Rose Feng
T-059
Characterize and Compare the Oral Pharmacokinetics of Two Atorvastatin Formulations in Healthy Chinese Male Subjects (Abstract) (Poster)
Kai Wang1, Wenfang Liu2, Gordon Amidon1, Meihua Rose Feng1
T-060
An oncology PBPK compound model library ¿ A contribution to the Open Systems Pharmacology Community (Abstract) (Poster)
Michael Block
T-061
Prediction of the effect of injection volume on the exposure to intrathecal (IT) drugs in the central nervous system (CNS) (Abstract) (Poster)
Michael Monine, Jenna M. Sullivan, Ajay Verma, Ivan Nestorov
T-062
Virtual Patient Strategies for Quantitative Systems Pharmacology Research (Abstract) (Poster)
Michael Weis, Christina Friedrich
T-063
Development of a Psoriasis PhysioPD Platform to Evaluate a Novel Therapy and Identify Uncertainties Critical to Efficacy and Competitive Differentiation (Abstract) (Poster)
Michael Weis [1], Katherine Kudrycki [1], Rebecca Baillie [1], Michael Reed [1], Anu Jauhan [2], Anna Dari [2], Sebastian Wachten [2], Marcel Froehlich [2], Wolfgang Prange [2], Roberta Bursi [2], Philipp Wabnitz [2]
T-064
Considerations for Adapting Previously Built Models for New Quantitative Systems Pharmacology Research (Abstract) (Poster)
Michael Weis, Rebecca Baillie, Christina Friedrich
T-065
Population Pharmacokinetic Analysis of Dabigatran in Bioequivalence Studies (Abstract) (Poster)
Mario Gonzlez-Sales, Lanyan Fang and Liang Zhao
T-066
Model Based Exposure-Response Analysis of Rivaroxaban to Assess the Adequacy of Current Bioequivalence Limits in Generic New Oral Anticoagulant Drugs (Abstract) (Poster)
Mario Gonzlez-Sales, Ph.D, Lanyan Fang, Ph.D, Myong-Jin Kim, Ph.D, Liang Zhao, Ph.D
T-067
Population pharmacokinetic model of methotrexate in Korean population (Abstract) (Poster)
Yun Seob Jung
T-068
Optimal dosing regimen design of phenytoin for Korean epilepsy patients: from premature baby to the elderly. (Abstract) (Poster)
Jinju Guk1,2, Dongwoo Chae1,2, and Kyungsoo Park1
T-069
Predictive Modeling of PCA Effect on Postoperative Pain Management (Abstract) (Poster)
Dongwoo Chae, Dong Woo Han, Kyungsoo Park
T-070
Factors Affecting Prediction Bias in Cumulative Amount Absorbed for Sustained-Release Drugs (Abstract) (Poster)
Delayed Verhulst-based indirect response models: maturation and oscillation (Abstract) (Poster)
Johannes Schropp (1), Gilbert Koch (2)
T-072
Model Aided Drug Invention Case Studies in Research: In silico differentiation for dual targeting PD-1 and Tim-3 in I/O, and predicting optimal drug properties of a bispecific biologic to maximize tissue targeting in OA (Abstract) (Poster)
John M Burke
T-073
Simulation Approach to Inform Modeling Analysis Plan to Assess Exposure-Response for Cognition Efficacy in an Alzheimer¿s Disease Study (Abstract) (Poster)
Julie A Stone, Huub J Kleijn, Marissa Dockendorf
T-074
Population Modeling of Longitudinal CD4+ T-cell Recovery in HIV-Infected Participants on Up to 15 Years of Antiretroviral Therapy: The Effect of Aging (Abstract) (Poster)
Systems Modeling of Left Ventricular Hypertrophy and Effect of Different Classes of Antihypertensive Therapies on Hypertrophy Regression (Abstract) (Poster)
Charles Van Brackle, Sergey Ermakov, K. Melissa Hallow
T-078
Ceftolozane/Tazobactam Dose Selection for Pediatric Patients (birth to <18 years) (Abstract) (Poster)
Kajal B. Larson, Yogesh T. Patel, Susan Willavize, Matthew L. Rizk, Brian Yu, Matthew G. Johnson, Elizabeth G. Rhee, and Luzelena Caro
T-079
Modeling and Visualization of Integrated Insulin and Glucose Time-Activity Profiles (Abstract) (Poster)
Karen Schneck, Lai San Tham, Ali Ertekin, Jesus Reviriego
T-080
Physiologically-based pharmacokinetic model of topical intra-vaginal HIV prevention (Abstract) (Poster)
Katherine Kay, Lisa C. Rohan, Dhavalkumar Shah, Robert Bies
T-081
Tenofovir Alafenamide (TAF) for HIV Prevention in IV Drug Users (Abstract) (Poster)
Modeling Suggests Synergistic Treatment Effect Following Combination Therapy of NKTR-214 and NKTR-262 in Tumor Bearing Mice (Abstract) (Poster)
Kavitha Bhasi, Phi Quach, Marlene Hennessy, Jose Zandro Aquino, Rhoneil Pena, Zhongxu (Michael) Ren, Haiying Cai, BoLiang Deng, Neel Anand, Myong Lee, Saul Kivimae, John Langowski, Jonathan Zalevsky and Werner Rubas
T-083
Two targets TMDD model described nonlinear pharmacokinetics of a bispecific antibody for Fibroblast Growth Factor Receptor 1/Klotho Complex in humans (Abstract) (Poster)
Kenta Yoshida1, Klas Petersson2, Jeff Wald2, Anders Viberg2, Leonid Gibiansky3, Leslie Chinn1, Angelica Quartino1
T-084
Development and Integration of a Dynamic Lactaion Model within a Full PBPK Model (Abstract) (Poster)
Khaled Abduljalil, Trevor N Johnson, Masoud Jamei
T-085
Mechanistic Pharmacokinetic Modeling Revealed Functional Increase in Bile Acid Efflux by the FXR Agonists Obeticholic Acid and Chenodeoxycholic Acid (Abstract) (Poster)
Cen Guo, Jeffrey Edwards, Carl LaCerte, Kimberly M. Freeman, Kenneth R. Brouwer, Kim L.R. Brouwer
T-086
Characterizing Time-Varying Clearance of Ipilimumab in Patients With Advanced Solid Tumors (Abstract) (Poster)
Kinjal Sanghavi, Amit Roy, Erin Dombrowsky, Akintunde Bello, Paul Statkevich, Shruti Agrawal, Heather Vezina
T-087
Predicting the Free Target Levels Based on Total drug and Total Target Levels for Monoclonal Antibodies (Abstract) (Poster)
Konstantinos Biliouris, Etienne Pigeolet, Philip J. Lowe, Ramprasad Ramakrinsha, Andrew Stein
T-088
A Regression Approach to Visual Predictive Checks for Population Pharmacokinetic and Pharmacodynamic Models (Abstract) (Poster)
Kris Jamsen, Kashyap Patel, Keith Nieforth, Carl Kirkpatrick
T-089
Development and application of a Quantitative Systems Pharmacology (QSP) model of complement pathway to evaluate treatments for autoimmune diseases (Abstract) (Poster)
Model-based meta-analysis of glucosuria-related adverse events in SGLT2 inhibitors (Abstract) (Poster)
Lulu Chu, Robert C. Penland, Gabriel Helmlinger, David Boulton
T-091
Towards A Quantitative Systems Pharmacology Approach to Evaluate the Anti-Obesity Potential of Oxidative Phosphorylation Uncouplers (Abstract) (Poster)
Lyndsey F. Meyer, Dhaval K. Shah
T-092
Population Pharmacokinetics of Mycophenolic Acid in Liver Transplant Recipients and a Comparison of FOCE and EM Estimation Methods (Abstract) (Poster)
H. Hu, B. Chen, X. Wang, M. R. Feng
T-093
Differential Impact of a target with high turnover on pharmacokinetics of antibodies with a range of binding kinetics in mice (Abstract) (Poster)
T-094
Characterizing Disease Progression for Parkinson¿s Disease to implement efficient trial designs (Abstract) (Poster)
Malidi Ahamadi, Daniela Conrado, Sreeraj Macha, Vikram Sinha, Timothy Nicholas, Brian Corrigan, Julie Stone, Kuenhi Tsai, Ian Watson, Massimo Bani, Pierandrea Muglia, Jackson Burton, Volker Kern, Diane Stephenson, Klaus Romero
T-095
Genome-wide association study (GWAS) using phenotypes estimated from a kinetic-pharmacodynamic model of chemotherapy-induced peripheral neuropathy (CIPN) (Abstract) (Poster)
Development and performance of npde for the evaluation of time-to-event model (Abstract) (Poster)
M. Cerou [1,2], M. Lavielle[3], K. Brendel[2], M. Chenel[2] and E. Comets[1]
T-097
Evidence-based design of fixed-dose combinations principles and application to pediatric anti-tuberculosis therapy (Abstract) (Poster)
Elin M Svensson, Gunnar Yngman, Paolo Denti, Helen McIlleron, Maria C Kjellsson, Mats O Karlsson
T-098
Semi-mechanistic modeling of dog tracer study data to quantify insulin action on glucose disposal rate and inhibition of lipolysis (Abstract) (Poster)
Maria E. Trujillo, Rolien Bosch, Eline M.T. van Maanen, Martijn van Noort, Peter Zafian, Judith Gorski, Pavan Vaddady, Tamara J. van Steeg, Sandra A.G. Visser
T-099
A JOINT MODEL-BASED META-ANALYSIS (MBMA) QUANTIFYING THE RELATIONSHIP BETWEEN PASI75 AND PASI SCORE IN PSORIASIS STUDIES (Abstract) (Poster)
Sima Ahadieh1, Carla Hernandez2, Mark Peterson3
T-100
Open Systems Pharmacology: An open source platform for joint development, exchange, review, qualification, and application of state-of-the-art tools and models for PBPK and Systems Pharmacology (Abstract) (Poster)
Martin Hobe
T-101
Modeling different progression endpoints and identifying prognostic factors in early Parkinson¿s disease (Abstract) (Poster)
An R-Shiny Web Application to Support Early Assessment and Decision Making of Oncology Studies Using Multivariate Tumor Growth Inhibition and Overall Survival Disease Models (Abstract) (Poster)
Mathilde Marchand 1, Laurent Claret2, Wan-Ting Lin2, Shang-Chiung Chen2, Helen Winter2, Sandhya Girish2, Jin Y. Jin2, Ren Bruno2
W-002
Population Pharmacokinetics of an anti-repulsive guidance molecule A (RGMa) antibody for treatment of multiple sclerosis, is well characterized by a 3 compartment model utilizing target mediated drug disposition (Abstract) (Poster)
Matthew Rosebraugh, Sandra Goss
W-003
Investigation of Body-Size-Based Dosing Regimens for vcMMAE Antibody-Drug Conjugates (ADC) (Abstract) (Poster)
Matts Kgedal, Leonid Gibiansky, Sandhya Girish, Jin Jin, Chunze Li
W-004
Insights from structural model deliniate PK associated with abuse potential following intranasal administration in recreational drug users (Abstract) (Poster)
Mehta Hiren1, Bernstein Galina1, He Jimmy1, Oldenhof John1, Mills Catherine1, Milovan Denise1, Setnik Beatrice1, Schmidt Stephan2, Nasrat Hakim3, Chris Dick3
W-005
Towards a fast and robust NLME parameter estimation algorithm in R (Abstract) (Poster)
Mikael Sunnker, Anne Kmmel, and Henning Schmidt
W-006
Using Bayesian Modeling to Optimize Antipsychotic Therapy (Abstract) (Poster)
Mohamed Ismail, Hiroyuki Uchida, Ariel Graff-Guerrero, Bruce G. Pollock, Robert Bies
W-007
Mechanistic PKPD modeling of anti-Flt1 monoclonal antibody (mAb) for Duchenne Muscular Disease in preclinical species (Abstract) (Poster)
Nancy Chen*, Dennis Keefe#, Devin Welty*
W-008
Modeling and Simulation of Time to Pain Relief of a Fast-Absorbing Ibuprofen Sodium Formulation (Abstract) (Poster)
Narayan Cheruvu1, Andreas Lindauer2, Per Olsson Gisleskog2, Cathy Gelotte1, and Brenda Zimmerman1
W-009
Highlighting Utility of Stable Isotope Approach to Support Dissolution Specifications for a Commercial Tablet Product with Tafenoquine, a long half-life compound (Abstract) (Poster)
Navin Goyal, Khadeeja Mohamed, Katie Rolfe, Terry Ernest, Maxine Taylor, Linda Casillas and Gavin Koh
W-010
A Longitudinal PKPD Model Describing the Effect of Ixekizumab on static Physician¿s Global Assessment score (sPGA) in Patients with Moderate-to-Severe Plaque Psoriasis (Abstract) (Poster)
Nieves Velez de Mendizabal, Michael Heathman, Kimberley Jackson
W-011
Grid search and chaos synchronization as a tool to uniquely estimate parameters of a chaotic pharmacological system (Abstract) (Poster)
Nikhil Pillai, Sorell L. Schwartz, Thang Ho, Aris Dokoumetzidis, Robert Bies, Immanuel Freedman
W-012
Population Pharmacokinetic Analysis of Bupropion XL and Its Three Metabolites in Chinese Subjects (Abstract) (Poster)
Xuan Zhou, Fan Zhang, Yucheng Sheng, Jingqiu Hu, Peiming Ma
W-013
Mechanistic Modeling of the Fidaxomicin Effects on Clostridium difficile Infection (Abstract) (Poster)
Peiying Zuo 1, Pete Bonate 1, Leticia Delgado-Herrera 1, Alejandro Palacios Fabrega 2, Andreas Karas 2
W-014
Network-based Systems Pharmacology Model to Identify Novel Treatment Strategies for Bortezomib-induced Peripheral Neuropathy (Abstract) (Poster)
Peter Bloomingdale, Donald E. Mager
W-015
Population-Based Pharmacokinetic Model for Intravenous Polymyxin B: A Quantitative Framework to Predict Pharmacokinetic Estimates in Patients with Gram-Negative Infections (Abstract) (Poster)
Pooja Manchandani1,*, Visanu Thamlikitkul2, Lawrence S. Lee3, Yanina Dubrovskaya4, Jessica T. Babic5, Vincent H. Tam1
W-016
Investigation of PK/PD relationship between an anti-ST2 antibody and soluble target using a target mediated drug disposition PK model (Abstract) (Poster)
Qun Jiao, Xiling Jiang, Chao Han, Donald L. Heald
W-017
An integrated PBPK/PD feedback model to predict drug-drug interactions between gastric acid reducing agents and drugs with pH dependent solubility (Abstract) (Poster)
Rachel H. Rose, Shriram Pathak, Masoud Jamei
W-018
A NOVEL SEMI-MECHANISTIC MODEL FOR PHARMACOKINETIC/PHARMACODYNAMIC MODELLING OF ANTI-TUMOR EFFICACY OF ANTIBODY DRUG CONJUGATES (Abstract) (Poster)
Renu Singh Dhanikula*, Amy Wiebesiek, Alexander Kozhich, Francis Lee, Tianxiang (Kevin) Han, Rama Iyer, Punit Marathe and Zheng Yang
W-019
A Time to Event Model for the Immunogenicity of Monoclonal Antibody X (Abstract) (Poster)
Dan Li, Yaping Zhang, Anna Schwendeman, Jane Ruppel, Helen Winter, Jin Y Jin, Rong Deng
W-020
Pharmacokinetic and Pharmacodynamic Properties of Lulizumab Pegol, an Anti- (Abstract) (Poster)
Rong Shi, Nilay Takkar, Bindu Murthy, Johanna Mora, Diane Shevell, Lara Pupim,
W-021
Mechanism-based PK-PD model for Brain Dopamine Responses by Methylphenidate in Rats (Abstract) (Poster)
Translation of semi-mechanistic neutropenia model for vc-MMAE antibody-drug conjugate (ADC) (Abstract) (Poster)
Jie Shao2, Zhichuan Li3, Dan Lu1, Cindy Xinyi Zhang1, Xin Wang1, Jin Jin1, Sandhya Girish1, Chunze Li1, Shang-Chiung Chen1
W-031
Influence of autosomal allelic bias on signal transduction through network motifs (Abstract) (Poster)
Shibin Mathew, Alexander Gimelbrant, Suzanne Gaudet
W-032
An application of PBPK-PD model to identify the target site of prolactin response induced by D2 receptor antagonists ¿ which is the target site, brain or plasma?- (Abstract) (Poster)
Shinji Shimizu1, Dirk-Jan van den Berg2, Robin Hartman2, Francisco Bellanti2, Elizabeth de Lange2
W-033
Implementation of distributed delays for absorption delays and delayed drug response (Abstract) (Poster)
Shuhua Hu, Michael Dunlavey, Serge Guzy, Nathan Teuscher
W-034
Population pharmacokinetics of andecaliximab, an inhibitor of MMP9, for the treatment of advanced solid tumors (Abstract) (Poster)
Vinay M Daryani, Sneha Gupta, Shringi Sharma, Yan Xin, Anita Mathias
W-035
Development and application of an integrated population pharmacokinetic model for rivaroxaban across multiple patient populations (Abstract) (Poster)
Stefan Willmann1, Liping Zhang2, Matthias Frede1, Dagmar Kubitza1, Wolfgang Mck1, Stephan Schmidt3, Alexander Solms1, Xiaoyu Yan2, Dirk Garmann1
W-036
Development of a Physiologically Based Pharmacokinetic ¿ Population Pharmacodynamic model for Oxycodone (Abstract) (Poster)
Carolina de Miranda Silva(1), Valvanera Vozmediano Esteban(2), Yosuke Nakatani(1), Naveen Mangal(1), Sumit Basu(1), Tanay Samant(1), Haitao Yang(1), Veronique Michaud(3), Jacques Turgeon(3), Lawrence Lesko(1), Stephan Schmidt(1)
W-037
Population Pharmacokinetics of Tenofovir (TFV) and Tenofovir Diphosphate (TFVdp) in the Blood, Semen, and Mononuclear Cells of HIV-Negative and Positive Men Receiving Tenofovir Disoproxil Fumarate (TDF) or Tenofovir Alafenamide (TAF) (Abstract) (Poster)
Stephen A. Greene, Jingxian Chen, Heather Prince, Brian Maas, Kaitlyn Maffuid, Katy Garrett, Craig Sykes, Amanda Schauer, Cynthia L. Gay, Angela DM Kashuba, Myron S. Cohen, Julie B. Dumond
W-038
A philosophical framework for integrating quantitative systems pharmacology models into pharmacometrics (Abstract) (Poster)
Stephen Duffull
W-039
A QSP Model of HIV to understand and predict virological failure from antiretroviral use (Abstract) (Poster)
Steven Sanche (1), Nancy Sheehan (1,2), Thibault Mesplde (3), Mark Wainberg (3), Jun Li (1), Fahima Nekka (1)
W-040
Model-Based Optimization of Folate Receptor-Mediated Targeting Delivery of Far-Red Light-Activatable Prodrugs to Ovarian Cancer Cells (Abstract) (Poster)
Even More Efficient Generation and Selection of Virtual Populations in Quantitative Systems Pharmacology Models (Abstract) (Poster)
Theodore Rieger, Richard Allen, Lukas Bystricky, Yuzhou Chen, Glen Colopy, Yifan Cui, Angelica Gonzalez, Yifei Liu, Rebecca White, Rebecca Everett, H. Thomas Banks, Cynthia Musante
W-042
A Pregnancy Physiologically Based Pharmacokinetic Model Verified For Different Drugs Metabolized And Eliminated Via Various Pathways (Abstract) (Poster)
Andre Dallmann, Ibrahim Ince, Juri Solodenko, Katrin Coboeken, Georg Hempel, Thomas Eissing
W-043
An Approach to Incorporating Variability into a Quantitative Systems Pharmacology Model for Diabetes (Abstract) (Poster)
Timothy H Waterhouse, Jennifer K Leohr, Jeanne S Geiser, Michael A Heathman
W-044
Development of a quantitative systems pharmacology model for prediction of mineralcorticoid receptor antagonists-induced hyperkalemia (Abstract) (Poster)
Evaluation of Dosing Strategy for Pembrolizumab for Oncology Indications (Abstract) (Poster)
Tomoko Freshwater, Anna Kondic, Malidi Ahamadi, Claire H Li, Rik de Greef, Dinesh de Alwis, Julie A Stone
W-046
Predicting Phase III Efficacy and Safety in Insulin Response using QSP Modeling (Abstract) (Poster)
David R Hagen, Guido H. Jajamovich, Craig Fancourt, Brian Topp, Maria E. Trujillo
W-047
A QSP approach to predict clinical outcomes of thiopurine therapy in inflammatory bowel disease (Abstract) (Poster)
1. Vijay K. Siripuram 2. Daniel F.B. Wright 3. Murray L. Barclay 4. Stephen B. Duffull
W-048
Model-based evaluation of the relationship between lymph node response and progression-free survival (PFS) in idelalisib-treated relapsed/refractory chronic lymphocytic leukemia (CLL) (Abstract) (Poster)
Vinay M Daryani, Shringi Sharma, Guan Xing, Anita Mathias
W-049
Bittersweet: A neuroendocrine quantitative systems pharmacology model linking environmental stressors to glucose homeostasis (Abstract) (Poster)
WanYun Cheng, Samantha J. Snow, Mehdi Hazari, Urmila P. Kodavanti, Rory Conolly
W-050
Population Pharmacokinetics (PK) and Exposure-Efficacy Analyses of Nivolumab in Subjects with Advanced Hepatocellular Carcinoma (HCC) (Abstract) (Poster)
Xiaoli Wang,1* Elizabeth Ludwig,2 Caroline Passarell,2 Bradly Boone,1 Adyb Baakili,1 Christine Dela Cruz,1 Amit Roy,1 Matthew Hruska1
W-051
Characterization of Dasatinib Pharmacokinetics and Exposure-Response In Support of Dose Recommendations in Pediatric Patients with Philadelphia Chromosome Positive Chronic Myeloid Leukemia (Ph+ CML) In Chronic Phase (CP) (Abstract) (Poster)
Xiaoning Wang, Akintunde Bello and Amit Roy
W-052
Ribociclib (KISQALI) Population Pharmacokinetics (PopPK) and Exposure-Response (E-R) Analysis of Neutropenia (Abstract) (Poster)
Quantification of postmenopausal osteoporosis population: An system pharmacology approach using bisphosphonates. (Abstract) (Poster)
Yi Ting(Kayla) Lien1, Kumpal Madrasi2, Snehal Samant1, Myong-Jin Kim2, Fang Li2, Stephen Voss3, Theresa Kehoe3, Li Li2, Stephan Schmidt1
W-054
Population Pharmacokinetics of Recombinant Fusion Protein Linking Coagulation Factor IX with Recombinant Albumin (rIX-FP) in Adult and Pediatric Patients with Severe Hemophilia B (Abstract) (Poster)
Ying Zhang, John Roberts, Christine Voigt, Iris Jacobs, Jagdev Sidhu
W-055
Assessment of CYP1A2 inductive potential of edaravone using PBPK model (Abstract) (Poster)
Regulatory perspective on population pharmacokinetics analysis and exposure-response analysis in drug development and M&S related guidance development in Japan (Abstract) (Poster)
Prediction of CYP3A drug-drug interactions for DSTA4637S, an anti-Staphylococcus aureus THIOMABTM antibody-antibiotic conjugate using physiologically-based pharmacokinetic model (Abstract) (Poster)
Yaping Zhang, Rong Deng, Victor Yip, Ben-Quan Shen, Cyrus Khojasteh, Chenguang Zhou, Amrita Kamath, William Hanley, Yuan Chen
W-058
Human dose prediction for an agonist monoclonal antibody targeting receptors distributed in both peripheral and CNS (Abstract) (Poster)
Yucheng Sheng, Robert Biddlecombe, Chenbing Guan, Yuanyuan Ji, Peiming Ma
W-059
Quantitative Systems Pharmacology (QSP) modeling as a systematic approach for drug combination evaluation in Immuno-Oncology (IO) (Abstract) (Poster)
Lurasidone Exposure-Response in Pediatric Bipolar Depression: Simulation and Comparison to Adults (Abstract) (Poster)
Sunny Chapel, Yu-Yuan Chiu, Jongtae Lee, Felix Agbo, Antony Loebel
W-061
Global sensitivity analysis of a mathematical model of the effects of a cyclin-dependent kinase inhibitor on cell cycle progression (Abstract) (Poster)
Zack W. Jones, Haley R. Houke, Martine F. Roussel, Rachel N. Leander, Clinton F. Stewart, John C. Panetta
W-062
A Web-based Dashboard System for Dose Individualization of Vancomycin (Abstract) (Poster)
Yu-cheng Gao, Chen Xie, Jian-jun Gao, Hong Huang, Zheng Jiao
W-063
Development of a parsimonious dose-to-mother deuterium technique to assess exclusivity of breastfeeding practice in low-income countries (Abstract) (Poster)
Zheng Liu1, Aly Diana1,2,3, Christine Slater4, Thomas Preston5, Rosalind S. Gibson2, Lisa Houghton2, Stephen B. Duffull1
W-064
A population-based target-mediated drug disposition model to predict clinical pharmacokinetics of BMS-986090, an anti-CD40 antagonistic domain antibody (Abstract) (Poster)
Shuang Liang, Haiqing Wang, Rong Shi, Rong Liu, Anish Suri, Suzanne Suchard, Steve Nadler, Marek Honczarenko, Uma Kavita, Vaishali Shah, John Throup, Ihab Girgis, Zheng Yang
W-065
Population Pharmacokinetic, Target Engagement and Pharmacodynamic Modeling of CNTO7160, an Anti-Interleukin-33R Monoclonal Antibody in Healthy Subjects (Abstract) (Poster)
Zhenling Yao, Ivo Nnane, Damien Fink, Tong-Yuan Yang, Frdric Baribaud and Zhenhua Xu
W-066
Population PK Analysis of Relebactam Lung Penetration Profile in Healthy Subjects (Abstract) (Poster)
Zufei Zhang, Eric C. Mangin, and Matthew L. Rizk
W-067
Performance of target-mediated drug disposition (TMDD) modeling compared with allometric extrapolation for establishing the first-in-human avelumab dosage (Abstract) (Poster)
A Model-Based Meta-Analysis (MBMA) of Pharmacokinetic Drug Interactions: Run One, Know Everything (Abstract) (Poster)
Kiranmai Ganji (1), Premsagar Kummari (1), Ramanatha Saralaya (1), Nand Kishore Rawat (2), William S Denney (3)
W-069
Population Pharmacokinetics and Exposure-Response Analyses for Abatacept in Juvenile Idiopathic Arthritis (Abstract) (Poster)
X Li, JA Passarell, K Lin, A Roy, B Murthy, IG Girgis
W-070
Physiologically-Based Pharmacokinetic Modeling Prediction of CYP3A4 and CYP1A2 Inhibition or Induction on Exposure of Olanzapine and Samidorphan Given in Combination as ALKS 3831 (Abstract) (Poster)
Lei Sun, Lisa von Moltke, Karen Rowland Yeo
W-071
Population modeling of pre-bronchodilator FEV1 response to benralizumab treatment in patients with severe asthma (Abstract) (Poster)
Li Yan1, Bing Wang1, Binbing Yu2, Peter Barker3, Mitchell Goldman3, Lorin Roskos2
W-072
Population Pharmacokinetic and Pharmacodynamic Modeling of Thymus and Activation-Regulated Chemokine (TARC) Response to Dupilumab in Uncontrolled Persistent Asthma (Abstract) (Poster)
Li Zhang, Meng Li, Zhaoling Meng, Yongtao Li, John D. Davis, Brian N. Swanson, Vanaja Kanamaluru, Qiang Lu
W-073
Exposure-Response Analysis of Dupilumab on Forced Expiratory Volume in 1 Second (FEV1) in Uncontrolled Persistent Asthma (Abstract) (Poster)
Li Zhang, Meng Li, Zhaoling Meng, Yongtao Li, John D. Davis, Brian N. Swanson, Vanaja Kanamaluru, Qiang Lu
W-074
Longitudinal Model-Based Meta-Analysis (MBMA) for rheumatoid arthritis with Monolix (Abstract) (Poster)
Geraldine Ayral (1) , Jonathan Chauvin (1)
W-075
New library of time-to-event (TTE) models for the MonolixSuite and application to two experimental data sets (Abstract) (Poster)
Geraldine Ayral (1), Jonathan Chauvin (1)
W-076
Population Pharmacokinetic and Exposure-Efficacy/Safety Analyses for Selection of Optimal Dose Regimen of Tocilizumab in Patients With Giant Cell Arteritis (GCA) (Abstract) (Poster)
Leonid Gibiansky,1 Ekaterina Gibiansky,1 Nicolas Frey,2 Navita L. Mallalieu,3 Claire Petry,2 Jean-Eric Charoin,2 Neil Collinson,4 Joy C. Hsu3
W-077
Bridging from Intravenous to Subcutaneous Formulation of Tocilizumab for Optimal Dose Regimens in Polyarticular Juvenile Idiopathic Arthritis (pJIA) (Abstract) (Poster)
Leonid Gibiansky,1 Ekaterina Gibiansky,1 Nicolas Frey,2 Navita L. Mallalieu,3 Claire Petry,2 Jean-Eric Charoin,2 Wendy Douglass,4 Joy C. Hsu3
W-078
Population Pharmacokinetic and Exposure-Efficacy/Safety Analyses for Bridging J-ALEX to Global Population with Alectinib 600mg BID Dose Regimen (Abstract) (Poster)
Joy C. Hsu,1 Felix Jaminion,2 Elena Guerini,2 Tomohiro Tanaka,3 Sophie Golding,2 Bogdana Balas,2 Ali Zeaiter,2 Peter N. Morcos,1 Nicolas Frey2
W-079
Clearance over time and effect of response in the pharmacokinetics of avelumab (Abstract) (Poster)
Population Pharmacokinetic (PopPK) and Exposure Response (E-R) Analyses for Olaparib Tablet Formulation in a Phase III study (SOLO2) in Patients with Ovarian Cancer (Abstract) (Poster)
Jianguo Li1, Hongmei Xu1, Maria Learoyd 2, Khanh Bui1, Helen Tomkinson2, and Nidal Al-Huniti1
W-082
Evaluation of computational platforms, model structures, and 90% confidence interval (CI) estimation methods in the linear mixed-effects modeling of drug concentration vs. change-from-baseline QTc (C-¿QTc) relationships (Abstract) (Poster)
Jingtao Lu, Nidal Al-Huniti, Eric Masson, Gabriel Helmlinger, Jianguo Li
W-083
Assessment of Tumor-Size Response Metrics to Predict Progression Free Survival (PFS) in Patients With Second-Line Advanced Breast Cancer (ABC) (Abstract) (Poster)
Yanke Yu; Wan Sun, Diane Wang
W-084
Prediction of Progression-Free Survival from Phase 2 to Phase 3 Using Early Tumor Response Data in First Line Advanced Breast Cancer (Abstract) (Poster)
Wan Sun, Yanke Yu, Diane Wang
W-085
Characterization of body temperature, heart rate and sleeping patterns in preterm neonates (Abstract) (Poster)
Gilbert Koch (1), Marc Pfister (1), Sven Schulzke (2), Kerstin Jost (2), Alexandre N. Datta (3)
W-086
The Impact of Particle Size in the Delivery of Drugs by Inhalation (Abstract) (Poster)
Guido H. Jajamovich, Antonio Cabal, Khamir Mehta, Peng Guo, Andrzej Przekwas
W-087
Radiogenomic Analysis of Diffusion-Weighted MRI and Genomic Data to Inform Treatment of Glioblastoma (Abstract) (Poster)
Guido H. Jajamovich, Chandni R. Valiathan, Razvan Cristescu, Sangeetha Somayajula
W-088
A Quantitative Systems Pharmacology Model of Glucose Responsive Insulin (Abstract) (Poster)
Craig Fancourt, Sandra A.G. Visser, Maria Trujillo, Brian Topp
W-089
Can Anti-Obesity-Drug-Induced Terminal Body Weight Loss be Predicted from Initial Caloric Intake Reduction, Independent of Obesity Drug Class? (Abstract) (Poster)
Craig Fancourt, Maria Trujillo, Ryan Vargo, Sandra A.G. Visser
W-090
Application of Physiologically Based Pharmacokinetic (PBPK) Modeling to Predict Desloratadine Pharmacokinetics in Children (Abstract) (Poster)
W. Zhou1, T. Johnson2, K. Bui1, S.Y.A. Cheung3, J. Li1, H. Xu1, N. Al-Huniti1, D. Zhou1
W-091
Joint modeling of overall survival (OS) and tumor size for patient-level predictions of survival in non-small cell lung cancer (NSCLC) (Abstract) (Poster)
Dmitry Onishchenko(1), James Dunyak(2a), Eric Masson(2a), Gabriel Helmlinger(2a), Kirill Peskov(1), Helen Tomkinson(2c), Donald Stanski(2b), Nidal Al-Huniti(2a)
W-092
Mechanistic Population PK/PD Modeling of a Bispecific Antibody in Nonhuman Primates: Impact of Immunogenicity. (Abstract) (Poster)
Olivia Campagne, Audrey Delmas, Sylvain Fouliard, Marylore Chenel, Gurunadh R. Chichili, Hua Li, Ralph Alderson, Jean-Michel Scherrmann, Donald E. Mager
W-093
Quantitative Proteomics and Network Simulations for 3 Patient-Derived Xenograft Models of Pancreatic Cancer (Abstract) (Poster)
Jin Niu, Shichen Shen, Jun Qu, Robert M. Straubinger, Donald E. Mager
W-094
Joint modeling of time-evolving tumor load and survival: an approach to rationally design treatment sequencing, staging, and dosing strategies for oncology combinations (Abstract) (Poster)
James Dunyak, Dmitry Onishchenko, Eric Masson, Gabriel Helmlinger, Helen Tomkinson, Kald Abdallah, Don Stanski, Nidal Al-Huniti
W-095
Seamless population PK workflow in R - from data review, to model development, to report writing. (Abstract) (Poster)
Helena Edlund1, Devin Pastoor2, Tarjinder Sahota1, Robert Fox1, Nidal Al-Huniti1
W-096
Bayesian formulation of a joint model of longitudinal tumor size and overall survival (OS) in Non-Small Cell Lung Cancer (NSCLC) (Abstract) (Poster)
Nidal Al-Huniti, James Dunyak, Sergey Aksenov, Diansong Zhou, Hongmei Xu, Eric Masson, Gabriel Helmlinger, Helena Edlund, Donald Stanski
W-097
Redefining normal variability of drug pharmacokinetics (Abstract) (Poster)
Hesham S Al-Sallami, Song Lim Cheah, Shiou Yii Han, Joel Liew, Jin Lim, Mary Anne Ng, Hayneil Solanki, Run Jie Soo, Victoria Tan, Stephen Duffull
W-098
The use of fat-free mass to describe the dose-response relationship of unfractionated heparin in children (Abstract) (Poster)
Hesham S Al-Sallami, Fiona Newall, Paul Monagle, Vera Ignjatovic, Noel Cranswick, Stephen Duffull
W-099
Tobramycin dose individualization using the MonolixSuite (Abstract) (Poster)
Geraldine Ayral (1), Marc Lavielle (2)(3) , Jonathan Chauvin (1)
W-100
New library of target-mediated drug-disposition (TMDD) models for the MonolixSuite (Abstract) (Poster)
